Recruiting

Testing a nasal spray to slow memory loss in early Alzheimer's disease

Plain-English translation of NCT06489548 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a medication called Foralumab, which is given as a nasal spray, to see if it can help slow memory loss and reduce inflammation in the brain in people with early Alzheimer's disease. The medication works by activating immune cells in the brain called microglia. Researchers will measure how safe the treatment is and whether it changes brain inflammation using special imaging scans.

Early Alzheimer's disease causes progressive memory loss and cognitive decline, and there are limited treatment options available today. This medication has shown promise in animal studies of Alzheimer's disease, so researchers want to test whether it is safe and effective in people with early memory problems.

Do you qualify?

You likely qualify if…

you are between 60 and 85 years old
you have been diagnosed with early symptomatic Alzheimer's disease with mild memory problems
you have an amyloid-positive PET brain scan or prior evidence of amyloid in your spinal fluid or brain imaging
you are in generally good health with no other serious neurologic diseases
you have been on a stable medication regimen for at least eight weeks and can remain stable during the study
you have a study partner (family member or close friend) who can regularly check on you during the trial

You likely don't qualify if…

you have a history of other brain diseases such as Parkinson's disease, stroke, Lewy body dementia, or multiple sclerosis
you are currently taking immune-suppressing medications, corticosteroids, or immunomodulatory drugs
you have a history of autoimmune disease
you have a history of major depression in the past year, bipolar disorder, or schizophrenia
you have uncontrolled high blood pressure, diabetes, or significant heart, lung, kidney, or liver disease

What participation looks like

You would receive the nasal spray (or placebo) three times per week on Mondays, Wednesdays, and Fridays for two weeks, then take one week off. This pattern repeats four times over three months. You will have visits at Brigham and Women's Hospital in Boston for initial treatment and cognitive testing, with follow-up visits at the research center. You'll also undergo brain imaging (PET scans) and blood tests to monitor safety and measure changes in brain inflammation.

AI-generated summary from trial data · Jul 1, 2026 · Not medical advice

Testing a nasal spray to slow memory loss in early Alzheimer's disease

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)